Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 20/20 | 0.76 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14276754 | 0.91 | SLC9A1 (0.77) | SLC9A1SLC9A2 | |
| SCHEMBL14276839 | 0.86 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| SCHEMBL30772134 | 0.86 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| SCHEMBL14276853 | 0.84 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| SCHEMBL14276871 | 0.83 | SLC9A1 (0.72) | SLC9A1SLC9A2 | |
| SCHEMBL14276741 | 0.83 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| SCHEMBL14276743 | 0.80 | SLC9A1 (0.74) | SLC9A1SLC9A2 | |
| SCHEMBL14276893 | 0.80 | SLC9A1 (0.82) | SLC9A1SLC9A2 | |
| SCHEMBL14276752 | 0.78 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| SCHEMBL14276906 | 0.77 | SLC9A1 (0.73) | SLC9A1SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334880-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL DISEASES | JANSSEN R&D IRELAND (IE) | 2017-11-23 | — | — | US | disclosed |
| US-9725432-B2 | Pyrimidine derivatives for the treatment of bacterial diseases | JANSSEN SCIENCES IRELAND US (IE) | 2017-08-08 | — | — | US | disclosed |
| US-20150087651-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087651-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL DISEASES | TYMS, UMPS, TYMP | SLC9A1 667/4885SLC9A2 1075/4885 |
| US-20170334880-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL DISEASES | TYMS, UMPS, TYMP | SLC9A1 667/4885SLC9A2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.